SMI-4a（b）

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

(Z)-SMI-4a is a selective ATP-competitive Pim-1 kinase inhibitor with an IC50 of 21 nM.

SMI-4a is a potent and selective Pim protein kinase inhibitor, which blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma. SMI-4a was found to induce phosphorylation of extracellular signal-related kinase1/2 (ERK1/2), and the combination of SMI-4a and a mitogen-activated protein kinase kinase 1/2 (MEK1/2) inhibitor was highly synergistic in killing pre-T-LBL cells. SMI-4a may be developed as a therapeutic strategy for the treatment of pre-T-LBL.

SMI-4a; SMI4a; SMI 4a; TCS PIM-1 4a.

GPCR/G Protein

Antibacterial

Pim1

Cancer

——

438190-29-5

273.23

C11H6F3NO2S

98%

——

c1cc(cc(c1)C(F)(F)F)/C=C\1/C(=O)NC(=O)S1

5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione

(-20℃)

With Ice Pack

≥ 2 years